KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 49 Publications

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG4PI1KSzVyPUOuNlc{PTJizszN NHPaTI1USU6JRWK=
HuO-3N1 M4HOdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PabGlEPTB;ND6xO|E1OiEQvF2= NHrifnhUSU6JRWK=
LAMA-84 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTRwNUi0OlUh|ryP MlvhV2FPT0WU
CAL-72 MmPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXTTWM2OD13LkS4NFg1KM7:TR?= MmnEV2FPT0WU
LoVo NEHY[mdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTZwOUOyN|kh|ryP MknpV2FPT0WU
HH NXmwdmlUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVnJR|UxRThwMke2O|Eh|ryP NYm4R3hpW0GQR1XS
SK-MEL-3 NVvwboxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{e0bmlEPTB;OD6yPFU4PSEQvF2= NHrpZ49USU6JRWK=
KM12 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTlwMkGxOFIh|ryP M3PXWnNCVkeHUh?=
NCI-H1437 M2nqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonYTWM2OD17LkiwPVch|ryP NX71UZVLW0GQR1XS
NCI-H1838 M3X4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFzLkG4OlUh|ryP NFG5dG9USU6JRWK=
J-RT3-T3-5 MoTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkOxTWM2OD1zMT6yOFE4KM7:TR?= MlzSV2FPT0WU
GOTO MofWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LOfWlEPTB;MUGuOlk6PiEQvF2= M4LPNXNCVkeHUh?=
LB2241-RCC MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGmzWlZKSzVyPUGxMlcyQDZizszN MYXTRW5ITVJ?
ES7 M1ywfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjxTWM2OD1zMT63PFgh|ryP MmCyV2FPT0WU
KP-N-YS NFL1[ZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVf2WItpUUN3ME2xNk43OzV2IN88US=> MmTTV2FPT0WU
CAL-12T NWHMOGNoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITaNnRKSzVyPUGzMlYyPyEQvF2= MYLTRW5ITVJ?
COLO-684 NGDodmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWGwb49oUUN3ME2xOE4yPTZ7IN88US=> NXewRYpRW0GQR1XS
DOK NV:xemRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfSWY1vUUN3ME2xOU4{OzJ7IN88US=> NF7oRZBUSU6JRWK=
Hs-578-T M33FOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvnOppKSzVyPUG1MlQyQDJizszN M{HURnNCVkeHUh?=
D-423MG NWrLS5h[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTF3LkWyN|Yh|ryP NWrVTXdQW0GQR1XS
DBTRG-05MG NEjsN2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{HTSWlEPTB;MUWuOlEyOSEQvF2= NYrneXJDW0GQR1XS
VM-CUB-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jWPWlEPTB;MUWuPVg1QSEQvF2= NEHoN3dUSU6JRWK=
KG-1 MlzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUL6TXNoUUN3ME2xOk4xQTl4IN88US=> M37jdHNCVkeHUh?=
8305C MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHJV3FKSzVyPUG2MlE5QDlizszN NGXFSolUSU6JRWK=
HuH-7 NIjyeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{KwNGlEPTB;MU[uNlY4PCEQvF2= NX7FPJBVW0GQR1XS
LXF-289 NYG4UGF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1Lxe2lEPTB;MU[uNlc1PyEQvF2= NFm5SG1USU6JRWK=
NCI-H1793 M{e5WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTsPW9WUUN3ME2xOk41PzF{IN88US=> MW\TRW5ITVJ?
ChaGo-K-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvn[GlmUUN3ME2xOk43PTZ6IN88US=> MnTjV2FPT0WU
GCIY NUHKXnl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;hTWM2OD1zNj63PVA2KM7:TR?= M1q2[HNCVkeHUh?=
SK-MEL-28 M3PkVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETCSnNKSzVyPUG3MlA1PzVizszN Mn3QV2FPT0WU
NCI-SNU-1 NIPlU|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzlW2JKUUN3ME2xO{4yOjZ7IN88US=> NYGxO44xW0GQR1XS
CTB-1 NYLXZo9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXtSnFrUUN3ME2xO{4zOjV7IN88US=> NH\FbHNUSU6JRWK=
NCI-H82 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrrfWJKSzVyPUG3MlQ2PzNizszN M{jHWXNCVkeHUh?=
HCC2998 NEXOfVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLvTXpEUUN3ME2xO{43PzN|IN88US=> M{S4fHNCVkeHUh?=
NCI-H2030 NG\vbo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVTvUJlKUUN3ME2xPE4yQTl5IN88US=> NFK0d5ZUSU6JRWK=
HuP-T3 NYj4fVhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF6LkW4PFgh|ryP NYDPdZozW0GQR1XS
697 NIK0NIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjxfohKSzVyPUG5MlAzODFizszN NX;WXnZFW0GQR1XS
MLMA MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fR[WlEPTB;MUmuNFU2PyEQvF2= M2PmNnNCVkeHUh?=
HCC70 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPveZJ5UUN3ME2xPU41QDlizszN M3nDeHNCVkeHUh?=
A704 NFTScmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1O2cGlEPTB;MUmuPFMxPSEQvF2= Mlj1V2FPT0WU
D-283MED NVrMSGszT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrXO4VKSzVyPUKwMlU{OzlizszN MojSV2FPT0WU
U031 M1O1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX6TWM2OD1{MT6xOFg6KM7:TR?= M4fCSHNCVkeHUh?=
HSC-3 Mk\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvGTWM2OD1{MT6xPFM2KM7:TR?= MX;TRW5ITVJ?
JVM-3 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFr1eWJKSzVyPUKyMlUxPiEQvF2= MV7TRW5ITVJ?
Mewo NHK5[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DYXWlEPTB;MkKuOVA4OyEQvF2= MXHTRW5ITVJ?
YH-13 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTJ{LkWxNlMh|ryP Mli3V2FPT0WU
LB1047-RCC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJ{LkW4O|kh|ryP MVTTRW5ITVJ?
HCC2157 NITTRohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV7JR|UxRTJ{LkiwOVQh|ryP NFrjeFRUSU6JRWK=
SNU-449 M3y3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJ{Lki3OFgh|ryP MnnoV2FPT0WU
Ramos-2G6-4C10 M4PwXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnizTWM2OD1{Mj65OkDPxE1? MWTTRW5ITVJ?
CHL-1 NUDHZ5JwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTJ|LkeyPVIh|ryP MVrTRW5ITVJ?
SK-MEL-30 Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrYfXJKSzVyPUK0MlQ3PjJizszN M2i1e3NCVkeHUh?=
PANC-08-13 NELuRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJ3LkC5N|gh|ryP NITPcGNUSU6JRWK=
QIMR-WIL Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DDWGlEPTB;MkWuNVg2QCEQvF2= MVLTRW5ITVJ?
BFTC-905 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fne2lEPTB;MkWuOVk1PCEQvF2= NYjxSJJmW0GQR1XS
GI-1 MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2KxSmlEPTB;MkWuO|A2PSEQvF2= MWXTRW5ITVJ?
MDA-MB-415 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTJ4LkWwN|Mh|ryP NE\hUGFUSU6JRWK=
GT3TKB M33tfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF:ycXVKSzVyPUK2MlU{PDJizszN MWfTRW5ITVJ?
DEL MoSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7xcFhSUUN3ME2yOk45OzV4IN88US=> M{jWV3NCVkeHUh?=
KOSC-2 NWnKPYxiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXu[|hKSzVyPUK2MlkxPzVizszN NVzCRZRnW0GQR1XS
RVH-421 Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M13UcWlEPTB;MkeuNlkzOSEQvF2= MoLMV2FPT0WU
EW-13 M2TUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2r6SmlEPTB;MkeuOFMxQCEQvF2= M131fHNCVkeHUh?=
639-V M2PDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ5LkWxNVkh|ryP NFv3ZYdUSU6JRWK=
A2780 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLETWM2OD1{Nz62OFEh|ryP MXXTRW5ITVJ?
SW982 M4\uZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfueXJzUUN3ME2yO{46ODV{IN88US=> M37zb3NCVkeHUh?=
SW1710 NH;wfIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4i5OWlEPTB;MkiuNFk5OSEQvF2= NGHUe3lUSU6JRWK=
HCC1569 NYmy[FZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\BNWlEPTB;MkiuOFg6PyEQvF2= NFLI[nlUSU6JRWK=
MV-4-11 MoLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTVVpJKSzVyPUK4MlU4OzVizszN NHLi[YhUSU6JRWK=
BHT-101 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PTeGlEPTB;MkiuOlU4OiEQvF2= NULsXFJzW0GQR1XS
Ca9-22 M{TRWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFv4ellKSzVyPUK4MlcyPCEQvF2= MVLTRW5ITVJ?
HAL-01 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrZb3VKSzVyPUK4Mlc3OTVizszN MmPVV2FPT0WU
D-263MG MonNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrFUJFKSzVyPUK5MlM1PCEQvF2= MVfTRW5ITVJ?
NEC8 NInTV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXIcZdXUUN3ME2yPU42PTR6IN88US=> Mlm1V2FPT0WU
EKVX NXjZfWtWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPIe3BKSzVyPUOxMlU5PDdizszN NF3BS2pUSU6JRWK=
EM-2 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnuR3BKSzVyPUOxMlY{ODRizszN NFK5ellUSU6JRWK=
MFM-223 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3nF[GlEPTB;M{GuPFA6QCEQvF2= MlXHV2FPT0WU
SK-PN-DW NUDzRZNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjGcWo1UUN3ME2zNk4yPDB4IN88US=> NXz0UJJFW0GQR1XS
HuO9 NH7HNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnEUYZKSzVyPUOyMlUzQDJizszN NYnwSFF7W0GQR1XS
MHH-PREB-1 NWH3c2kyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DjOmlEPTB;M{KuOlI{PCEQvF2= MXHTRW5ITVJ?
OVCAR-4 M1zLZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTN{LkizOlMh|ryP NXrLdlZbW0GQR1XS
NCI-H1648 M{LteWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXjWnBKSzVyPUOyMlg3PTFizszN M2PvZnNCVkeHUh?=
MKN1 NW[zWWw1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTN2LkGxNFEh|ryP MVjTRW5ITVJ?
KYSE-450 M4DEPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfjO2dKSzVyPUO0MlY1PDRizszN M4PhWHNCVkeHUh?=
ES8 NVHQRYV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK3TWM2OD1|ND64PVc2KM7:TR?= MYXTRW5ITVJ?
MS-1 NFe0UoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXETVd5UUN3ME2zOE46PTV2IN88US=> M1HoWXNCVkeHUh?=
HOP-92 NEHYT5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTN3LkmyO|ch|ryP M1HZ[XNCVkeHUh?=
SKG-IIIa MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTN4LkK1OlEh|ryP MVPTRW5ITVJ?
TE-11 NH3RSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjtWo1KSzVyPUO2MlUzPDNizszN NEjGTZJUSU6JRWK=
SK-NEP-1 M{TzWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTN5Lk[3OFQh|ryP MX3TRW5ITVJ?
DB NIrpVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTN5LkmxPFUh|ryP MoS4V2FPT0WU
IA-LM NVLwWZJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknuTWM2OD1|OD6wNlM6KM7:TR?= NVHVTpR1W0GQR1XS
COLO-829 MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTN6LkSxOVkh|ryP M3jOZ3NCVkeHUh?=
TGBC11TKB M4\HR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvmTWM2OD1|OT6xOFA5KM7:TR?= NIT5SHBUSU6JRWK=
CAL-51 MmXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHLtW|NKSzVyPUSwMlA3OTJizszN MUjTRW5ITVJ?
NCI-H2228 NWTlenRGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTRyLkO2OlIh|ryP NFjmfnFUSU6JRWK=
C32 MnrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;qTWM2OD12MD60NFI1KM7:TR?= MWjTRW5ITVJ?
KU-19-19 NUmwSHBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vIUWlEPTB;NECuO|Y5OyEQvF2= MVXTRW5ITVJ?
KNS-62 M2CzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\VRWlEPTB;NECuPFM5OSEQvF2= Ml;wV2FPT0WU
FADU NFi3SWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTRzLkK1NFIh|ryP MkPqV2FPT0WU
CAL-33 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nyO2lEPTB;NEKuOlc1QSEQvF2= MXPTRW5ITVJ?
CHP-134 M2ezTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\Be5A3UUN3ME20Nk45PDl4IN88US=> MV;TRW5ITVJ?
HDLM-2 NULhZpR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofsTWM2OD12Mj65NFg1KM7:TR?= NGTMVIVUSU6JRWK=
NBsusSR NYXnfIo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3lTWkyUUN3ME20N{4xPzJ3IN88US=> MVLTRW5ITVJ?
SW954 Ml;IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{TtXGlEPTB;NEOuNVA2OyEQvF2= NWDIb5A4W0GQR1XS
HCC1806 MnXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTFbnhqUUN3ME20N{41OTFizszN MYDTRW5ITVJ?
VMRC-RCZ MnrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jDZWlEPTB;NEOuOFU5PiEQvF2= MWDTRW5ITVJ?
A549 NHK1WFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTR|LkmzNUDPxE1? NFjBV3NUSU6JRWK=
NKM-1 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXKS3RYUUN3ME20N{46PTV6IN88US=> MmHHV2FPT0WU
DMS-273 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTR2Lke1Olch|ryP NIj4SFFUSU6JRWK=
TYK-nu NVHzRnBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{frXGlEPTB;NEWuNVI{PCEQvF2= MUfTRW5ITVJ?
KALS-1 M3TlSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\VWWlEPTB;NEWuNVQ3KM7:TR?= NUXkWnQxW0GQR1XS
A101D MlSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUCxfnJXUUN3ME20OU41PDV4IN88US=> MW\TRW5ITVJ?
G-361 M4PYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTR4LkKxN|gh|ryP NX7GdHByW0GQR1XS
KARPAS-299 NHz1XINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\MeWlEPTB;NE[uN|UyPiEQvF2= MYTTRW5ITVJ?
RS4-11 NG\Me2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{i4dWlEPTB;NE[uOVQzKM7:TR?= MWrTRW5ITVJ?
HT-1376 M{TlVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUi3Omh5UUN3ME20Ok44PDJ4IN88US=> M2DSZnNCVkeHUh?=
SK-N-AS MkfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[zT5hKSzVyPUS2Mlc5OjJizszN MVTTRW5ITVJ?
MG-63 Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTR4LkmwN|Yh|ryP Mm\SV2FPT0WU
EPLC-272H NFPubY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fKUWlEPTB;NE[uPVUxOyEQvF2= NFLQTXRUSU6JRWK=
BALL-1 MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFT3bnJKSzVyPUS3Mlg{OiEQvF2= NH7WOJpUSU6JRWK=
LCLC-97TM1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7YTWM2OD12OD6yNFIh|ryP NGSzZ49USU6JRWK=
HO-1-N-1 M3;UcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTR6Lkm2O|Yh|ryP NV7YdIlRW0GQR1XS
MFE-280 Moq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33MOWlEPTB;NEmuOFYyPyEQvF2= MVfTRW5ITVJ?
NCI-H526 NFT6V5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XqeGlEPTB;NEmuPFE3OyEQvF2= NYTCdJRzW0GQR1XS
D-566MG M{G0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zUcWlEPTB;NEmuPVA6PiEQvF2= NH:x[3ZUSU6JRWK=
BB30-HNC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3Ib4YyUUN3ME20PU46PDl6IN88US=> MVXTRW5ITVJ?
SK-N-DZ NXqy[|lyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3Pxe2lEPTB;NUCuNFQ5OSEQvF2= MonsV2FPT0WU
HepG2  NH;MW4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfWdpcxOTEEoN88US=> M{DaZlI1KGh? MnHIZoxw[2u|IGPDMWlKUTNvaX7keYNm\CCVIIDoZZNmKGG{cnXzeC=> MnjKNlU2OjdzMkO=
HepG2  NE\rcG1HfW6ldHnvckBCe3OjeR?= NVqydlRtOTEEoN88US=> NVS4UHhCOjRiaB?= NH7HPZJ{fXCycnXzd4V{KHSqZTDwbI9{eGixconsZZRqd26|IH;mJGFVVSCxbjDT[ZIyQThzLDDDbIsyKG:wIGPldlM1PSxiQ3jrNkBwdiCWaIK2PEwh[W6mIFPkb|Ihd25iVInyNVUhcW6mdXPl[EBjgSCVQz3JTWk{ NGjKdJozPTV{N{GyNy=>
KATO III  NWTzUo06T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;yNk42NzVxNz61JO69VQ>? M2K3e2ROW09? NUTXbo5q\W6qYX7j[ZMhfGinIITvfIlkcXS7IH;mJI9t[XCjcnni NEj0OYEzPDh2MUexPC=>
hTCEpi NXjFSlhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PDUVExKM7:TR?= NVPZcZdHTE2VTx?= NEnjfXdxemW4ZX70d{B1cGViY4n0c5BifGirYzDl[oZm[3Rib3[gTHNXNTF? NXT1TXVlOjR|N{C4N|U>
MCF10A Mk\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jwc|ExKM7:TR?= M3HWclI1KGh? NUnic5NWTE2VTx?= Mn\CdI91\W62aXH0[ZMhfGinIHP5eI91d3irY3n0fUBw\iCJQR?= M3PjVFI1OTVyNUm1
HL-60  MnHlSpVv[3Srb36gRZN{[Xl? NV:3RldUOTBizszN M2PtRVAvPSCq NXmyV2RXTE2VTx?= MXTy[YR2[2W|IIDoc5NxcG:{eXzheIlwdiCxZjDDbIszyqB? NVnvcJBPOjN7M{S0NVE>
MCF-7 NF7TW|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX[xMVExOM7:TR?= M2\ZRlI1KGh? MlHJSmJU NIm1ZWdqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:w MYGyN|E5PTN2Nx?=
HeLa  Ml:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYixMVExOM7:TR?= NXjlbHBuOjRiaB?= NH\LTlBHSlN? MnHIbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdg>? MoD3NlMyQDV|NEe=
SH-SY5Y Mm\LSpVv[3Srb36gRZN{[Xl? MoG4NVDDqM7:TdMg MlfBNlQhcA>? Mo\ybY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? NGXHTIIzOjZ{N{K5OC=>
IMR-32 M1:5[2Z2dmO2aX;uJGF{e2G7 MV6xNOKh|ryPwrC= MUiyOEBp M17MTIlvcGmkaYTzJINtcW:zdXnuc4wucW6mdXPl[EBxcG:|cHjvdplt[XSrb36gc4YheDV| NITQZZIzOjZ{N{K5OC=>
A549 MUTGeY5kfGmxbjDBd5NigQ>? M3;lZVExyqEQvF5CpC=> M4G3dVEhcA>? MUDzeZBxemW|c3XzJG5idm9vQ3:tbY5lfWOnZDDwOVMh[WOldX31cIF1cW:w MUSyNlU2QTN{MR?=
T47D  M4Tkd2Z2dmO2aX;uJGF{e2G7 NEjqcVkzOMLibV2= MnfCNlQhcA>? NInDb4lFVVOR NXLxblYyeHKndnXueJMhUVJvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBK|rqEzsG= MUSyNVE1PDhyNR?=
A29 MEF NV72d29xTnWwY4Tpc44hSXO|YYm= NVG1dJNrOTEEoN88UeKh MlPMNYg> M{X2[4Jtd2Otc9MgeIhmKHCqb4PwbI9zgWyjdHnvckBw\iCDa4SgZZQhW2W{NEezxsA> MUWyNFA2Ozd6MR?=
MDA-MB-453  NVHyWJdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHROU01OCEQvF2= MnS1O|IhcA>? NH7W[FlKSzVyIH;mJFExKM7:TR?= NFvQc2MzODB3M{e4NS=>
PC-3 NHrpWFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPHOU01OCEQvF2= NYjqdWR5PzJiaB?= MUDJR|UxKG:oIEGwJO69VQ>? MWCyNFA2Ozd6MR?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-AKT(Ser473) / p-AKT(Thr308); 

PubMed: 22739265     


Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖

PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; 

PubMed: 22739265     


ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤

ATM-S1981 / ATM / p-p53(S15) / p53 ; 

PubMed: 20639198     


Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖

p21 / p27 / p53 ; 

PubMed: 20177072     


HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.

22739265 20639198 20177072
Immunofluorescence
p-S824 KAP1 / ZEBRA ; 

PubMed: 28249048     


HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.

28249048
In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]
+ Expand

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]
+ Expand
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]
+ Expand
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Formulation: --
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO and 47.5% PEG300
For best results, use promptly after mixing. 		10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2
CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products4

  • AZD6738 New

    AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.

  • CHIR-99021 (CT99021) New

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.

  • Dorsomorphin (Compound C) New

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • VE-821

    VE-821 is a potent and selective ATP competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM in cell-free assays, shows inhibition of H2AX phosphorylation, minimal activity against PIKKs ATM, DNA-PK, mTOR and PI3Kγ.

  • KU-60019

    KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM in cell-free assays, 270- and 1600-fold more selective for ATM than DNA-PK and ATR,and is a highly effective radiosensitizer.

    Features:Improved analog of KU-55933, and is more effective at blocking ATM-mediated DDR events.

  • Berzosertib (VE-822|VX970|M6620)

    VE-822 is an ATR inhibitor with IC50 of 19 nM in HT29 cells.

    Features:VE-822 is a highly selective and potent derivative of the ATR inhibitor VE-821.

  • Chloroquine diphosphate

    Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator.

  • AZ20

    AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.

    Features:AZ20 is the first reported inhibitor of ATR protein kinase demonstrating tumor growth inhibition in vivo.

  • CP-466722

    CP-466722 is a potent and reversible ATM inhibitor, does not affect ATR and inhibits PI3K or PIKK family members in cells.

  • ETP-46464

    ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.

    Features:Selective ATR inhibitor and particularly toxic to p53-deficient cancer cells. Often used as a pharmacologic probe due to its ideal pharmacological properties.

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID